secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001628280-25-038329
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway
-----------------------------------------------------------------------------

- Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.
- Cash, investments $892.1M, down $127.7M sequentially; runway into mid-2027.
- ECLIPSE registrational program for chronic hepatitis Delta fully underway; ECLIPSE 2 and 3 enrolling patients.
- First patient dosed in Phase 1 of VIR-5525 (EGFR-targeting PRO-XTEN T-cell engager); three PRO-XTEN Phase 1 studies ongoing.
- R&D expenses $97.5M (down from $105.1M) reflecting restructuring savings partially offset by clinical costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025038329/0001628280-25-038329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025038329/vir-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer